When Transcriptomics Meets Drug Repurposing

PharmaLex, a company involved in digital innovation in the pharmaceutical industry, is utilizing transcriptomics to support drug repurposing. Transcriptomics involves studying the RNA molecules in a cell, allowing PharmaLex to identify potential drug candidates for repurposing. This approach can expedite the drug development process and potentially lead to the discovery of new treatments for various diseases.

Drug repurposing involves finding new therapeutic uses for established drugs, leveraging their safety profiles and pharmacological properties. Transcriptomics aids in analyzing gene expression patterns associated with diseases and treatments, identifying potential therapeutic targets, and understanding drug mechanisms in the context of repurposing. It also helps in discovering biomarkers for patient stratification and improving the efficiency of drug repurposing efforts.

Transcriptomic analysis has successfully repurposed drugs like thalidomide for multiple myeloma and metformin for cancer therapy. By studying the molecular effects of these drugs and identifying specific disease subtypes that respond to them, transcriptomics has proven its potential as a tool for identifying new therapeutic applications. Clinical trials have demonstrated the effectiveness of repurposed drugs like metformin in inhibiting tumor growth and improving patient outcomes